Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study-Reference-Cited by-同舟云学术

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Published:2021-03-25 Issue:5 Volume:30 Page:579-589
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Zhu Xiaoxue¹,Wu Min¹,Wang Hong²,Li Haijun³,Lin Junjie³,Peng Yun⁴,Hu Yue¹,Li Cuiyun¹^ORCID,Ding Yanhua¹

Affiliation:

1. Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China

2. Jilin Medical Products Administration, Changchun, China

3. Medical Affairs, Guangdong Raynovent Biotech Co., Ltd, Shenzhen, China

4. Medical Affairs, Guangdong Zhongsheng Pharmaceutical Co., Ltd, Dongguan, China

Funder

China National Major Scientific and Technological Special Project

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2021.1900822

Reference20 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease

3. Vitamin E and nonalcoholic fatty liver disease

4. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

5. Current efforts and trends in the treatment of NASH

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure–response approach;European Journal of Pharmaceutical Sciences;2024-08

2. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial;Nature Communications;2023-10-12

3. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review;Diabetes, Obesity and Metabolism;2023-02-28

4. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020;Clinical Pharmacology in Drug Development;2022-06-16